Therapeutic Innovation Australia (TIA) has announced the opening of the latest round of its Pipeline Accelerator scheme, which will focus on support for High Throughput Screening for small molecule drug discovery.
The Australian Therapeutic Pipeline (the “Pipeline”) is a TIA initiative to highlight the depth and breadth of Australian translational medical research capabilities. An objective of the Pipeline initiative is to enable researchers and industry (including SMEs) to access key translational research capabilities. This can leverage public sector investment in such capabilities and reduce duplication. To aid in this objective, TIA has developed a voucher-style researcher access scheme - the Pipeline Accelerator.
This round of the scheme will focus on supporting meritorious projects specifically related to drug discovery through screening of small molecule libraries against drug targets. Researchers from industry and academia are invited to apply for a voucher to reduce the cost of accessing one or more of a network of screening centres across the country. The projects can encompass pre-screening assay development, library screening and/or hit validation post-screening.
AusBiotech’s 2019 Industry Position Survey found a prevailing view across the life sciences sector that support diminishes as research leaves public institutions on the commercialisation pathway, and that the tech transfer and commercialisation support gap needs attention. It is strongly supportive of initiatives such as the Pipeline Accelerator scheme and encourages members to exercise these exemplary opportunities.
The scheme closes at 5pm (AEST) on Friday 15 November. For more information and to download the guidelines, visit: www.therapeuticinnovation.com.au/accelerator